Increase Throughput And Save Time

Oxford Biomedica is a leading, fully integrated, cell and gene therapy company, with an advanced lentiviral vector platform and have recently added adeno-associated virus (AAV) vectors capabilities. At the early stages of a new internal project the Early Development Group was able to quickly establish new assays, thanks to the fast turnaround time of the automated capillary-based assays performed using Jess™.

Find out how Jess™ has expanded Oxford Biomedica’s capabilities to develop future cell and gene therapy products.